AstraZeneca/ AZ-roundtable-debate-2017/ Roundtables Video roundtable – complete footage sally.macaulay@pharmaphorum.com 0 Comment Complete roundtable video debate on secondary prevention of recurrent atherothrombotic events Share X Video roundtable – complete footage https://pharmaphorum.com/roundtables/az-roundtable-debate-2017/video-roundtable-secondary-prevention-recurrent-atherothrombotic-events-among-high-risk-patients/
AstraZeneca/ AZ-roundtable-debate-2017/ Roundtables Video roundtable – Part 1 sally.macaulay@pharmaphorum.com 0 Comment Part 1 of the roundtable video debate on epidemiology and background of recurrent atherothrombotic events in high-risk patients Share X Video roundtable – Part 1 https://pharmaphorum.com/roundtables/az-roundtable-debate-2017/video-roundtable-epidemiology-background-recurrent-atherothrombotic-events-high-risk-patients-part-one/
AstraZeneca/ AZ-roundtable-debate-2017/ Roundtables Video roundtable – Part 2 sally.macaulay@pharmaphorum.com 0 Comment Part 2 of the roundtable video debate on the challenges to secondary prevention in current clinical practice Share X Video roundtable – Part 2 https://pharmaphorum.com/roundtables/az-roundtable-debate-2017/video-roundtable-challenges-secondary-prevention-current-clinical-practice-part-two/
AstraZeneca/ AZ-roundtable-debate-2017/ Roundtables Video roundtable – Part 3 sally.macaulay@pharmaphorum.com 0 Comment Part 3 of the roundtable video debate on the opportunity for improved secondary prevention of recurrent events among high-risk patients Share X Video roundtable – Part 3 https://pharmaphorum.com/roundtables/az-roundtable-debate-2017/video-roundtable-opportunity-improved-secondary-prevention-recurrent-atherothrombotic-events-among-high-risk-patients-part-three/